Literature DB >> 9523225

Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy.

H M Kantarjian1, F J Giles, S M O'Brien, M Talpaz.   

Abstract

This article begins with a review of the natural history of chronic myelogenous leukemia (CML), with an emphasis on prognostic features. Current standard therapy of CML with interferon-alpha based regimens, and interferon-alpha, in the context of allogenic stem cell transplantation is then discussed. Finally, some potentially effective novel agents including homoharringtonine, decitabine, ATRA, and topotecan are described.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9523225     DOI： 10.1016/s0889-8588(05)70496-2

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  8 in total

1.  A Study of Haemostatic Parameters in Patients of Chronic Myeloid Leukaemia.

Authors:  Ankur Jain; Naresh Gupta; Tejinder Singh; Sunita Agarwal
Journal:  J Clin Diagn Res       Date:  2016-07-01

Review 2.  Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.

Authors:  Christian Sillaber; Matthias Mayerhofer; Hermine Agis; Verena Sagaster; Christine Mannhalter; Wolfgang R Sperr; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

3.  Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia.

Authors:  Gonzalo Guevara; Jaime A González; Diego E Lopera; Manuel González; José D Saavedra; José Fernando Lobaton; Jorge Enrique Duque
Journal:  Colomb Med (Cali)       Date:  2012-12-30

4.  Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia.

Authors:  Sonya Haslam
Journal:  Core Evid       Date:  2005-03-31

Review 5.  Immunostimulatory DNA sequences and cancer therapy.

Authors:  G J Weiner
Journal:  Springer Semin Immunopathol       Date:  2000

6.  Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning.

Authors:  J Topaly; S Fruehauf; A D Ho; W J Zeller
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

Review 7.  Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib.

Authors:  Josephine Emole; Taiwo Talabi; Javier Pinilla-Ibarz
Journal:  Biologics       Date:  2016-02-26

8.  Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib.zzm321990A First of Its Kind Study on CML Patients of Kashmir

Authors:  Niyaz A Azad; Zafar A Shah; Arshad A Pandith; Mosin S Khan; Roohi Rasool; Javed Rasool; Shiekh A Aziz
Journal:  Asian Pac J Cancer Prev       Date:  2018-06-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.